Abus et dépendances aux produits psychoactifs : étude de consommations à travers l'enquête OPPIDUM 2004 du réseau des CEIP
Thérapie, 62 4 (2007) 337-346
Publié en ligne : 2007-11-06
Article cité par
La fonctionnalité Article cité par… liste les citations d'un article. Ces citations proviennent de la base de données des articles de EDP Sciences, ainsi que des bases de données d'autres éditeurs participant au programme CrossRef Cited-by Linking Program. Vous pouvez définir une alerte courriel pour être prévenu de la parution d'un nouvel article citant " cet article (voir sur la page du résumé de l'article le menu à droite).
Article cité :
Citations de cet article :
Dispositif pharmacoépidémiologique de surveillance des substances psychoactives : intérêts du programme national OPPIDUM du Réseau français d’addictovigilance
Elisabeth Frauger, Liselotte Pochard, Quentin Boucherie, et al.Therapies 72 (4) 491 (2017)
https://doi.org/10.1016/j.therap.2017.01.010
Benzodiazepines increase the reward effects of buprenorphine in a conditioned place preference test in the mouse
Lin‐Lin Ma, Thomas Freret, Mathilde Lange, Joanna Bourgine, Antoine Coquerel and Véronique Lelong‐BoulouardFundamental & Clinical Pharmacology 28 (6) 681 (2014)
https://doi.org/10.1111/fcp.12072
Misuse and Abuse of Pregabalin and Gabapentin: Cause for Concern?
Fabrizio SchifanoCNS Drugs 28 (6) 491 (2014)
https://doi.org/10.1007/s40263-014-0164-4
An Update on Zolpidem Abuse and Dependence
Caroline Victorri-Vigneau, Marie Gérardin, Morgane Rousselet, et al.Journal of Addictive Diseases 33 (1) 15 (2014)
https://doi.org/10.1080/10550887.2014.882725
Addiction médicamenteuse : quelles données pour évaluer et prévenir ?
Maryse Lapeyre-MestrePsychotropes Vol. 19 (1) 65 (2013)
https://doi.org/10.3917/psyt.191.0065
OPPIDUM surveillance program: 20 years of information on drug abuse in France
Elisabeth Frauger, Christophe Moracchini, Reynald Le Boisselier, David Braunstein, Xavier Thirion and Joëlle MicallefFundamental & Clinical Pharmacology 27 (6) 672 (2013)
https://doi.org/10.1111/fcp.12024
Assessment of abuse of tianeptine from a reimbursement database using ‘doctor‐shopping’ as an indicator
Frank Rouby, Vincent Pradel, Elisabeth Frauger, Vanessa Pauly, François Natali, Patrick Reggio, Xavier Thirion and Joëlle MicallefFundamental & Clinical Pharmacology 26 (2) 286 (2012)
https://doi.org/10.1111/j.1472-8206.2010.00906.x
Taux de pénétration des génériques de la buprénorphine haut dosage : principales tendances de 2006 à 2008
Christelle Boczek, Elisabeth Frauger, Joëlle Micallef, et al.Therapies 67 (2) 129 (2012)
https://doi.org/10.2515/therapie/2012011
Estimated magnitude of diversion and abuse of opioids relative to benzodiazepines in France
V. Pauly, V. Pradel, L. Pourcel, et al.Drug and Alcohol Dependence 126 (1-2) 13 (2012)
https://doi.org/10.1016/j.drugalcdep.2012.03.009
Which psychoactive prescription drugs are illegally obtained and through which ways of acquisition? About OPPIDUM survey
Elisabeth Frauger, Sandra Nordmann, Veronica Orleans, Vincent Pradel, Vanessa Pauly, Xavier Thirion and Joëlle MicallefFundamental & Clinical Pharmacology 26 (4) 549 (2012)
https://doi.org/10.1111/j.1472-8206.2011.00950.x
Patterns of Methylphenidate Use and Assessment of its Abuse and Diversion in Two French Administrative Areas Using a Proxy of Deviant Behaviour Determined from a Reimbursement Database
Elisabeth Frauger, Vanessa Pauly, François Natali, et al.CNS Drugs 25 (5) 415 (2011)
https://doi.org/10.2165/11587640-000000000-00000
Evidence of clonazepam abuse liability: results of the tools developed by the French Centers for Evaluation and Information on Pharmacodependence (CEIP) network
Elisabeth Frauger, Vanessa Pauly, Vincent Pradel, Frank Rouby, Jocelyne Arditti, Xavier Thirion, Maryse Lapeyre Mestre and Joëlle MicallefFundamental & Clinical Pharmacology 25 (5) 633 (2011)
https://doi.org/10.1111/j.1472-8206.2010.00882.x
Fatal poisoning due to snorting buprenorphine and alcohol consumption
Ophélie Ferrant, Frédérique Papin, Bénédicte Clin, et al.Forensic Science International 204 (1-3) e8 (2011)
https://doi.org/10.1016/j.forsciint.2010.05.015
Which indicators can public health authorities use to monitor prescription drug abuse and evaluate the impact of regulatory measures? Controlling High Dosage Buprenorphine abuse
Vanessa Pauly, Elisabeth Frauger, Vincent Pradel, et al.Drug and Alcohol Dependence 113 (1) 29 (2011)
https://doi.org/10.1016/j.drugalcdep.2010.06.016
Second Meeting of the French CEIP (Centres d’Évaluation et d’Information sur la Pharmacodépendance). Part I: How to Evaluate and Prevent the Abuse and Dependence on Hypnotic/Anxiolytic Drugs?
Joëlle Micallef-Roll and Maryse Lapeyre-MestreThérapie 64 (6) 355 (2009)
https://doi.org/10.2515/therapie/2009054
Chemical submission: results of 4-year French inquiry
S. Djezzar, F. Questel, E. Burin and S. DallyInternational Journal of Legal Medicine 123 (3) 213 (2009)
https://doi.org/10.1007/s00414-008-0291-x
Impact of a prescription monitoring program on doctor‐shopping for high dosage buprenorphine
Vincent Pradel, Elisabeth Frauger, Xavier Thirion, Eléonore Ronfle, Véronique Lapierre, Alain Masut, Christine Coudert, Olivier Blin and Joëlle MicallefPharmacoepidemiology and Drug Safety 18 (1) 36 (2009)
https://doi.org/10.1002/pds.1681
Estimation of clonazepam abuse liability: a new method using a reimbursed drug database
Elisabeth Frauger, Vanessa Pauly, Xavier Thirion, et al.International Clinical Psychopharmacology 24 (6) 318 (2009)
https://doi.org/10.1097/YIC.0b013e328330ae4b
Comparison of Five Benzodiazepine-Receptor Agonists on Buprenorphine-Induced μ-Opioid Receptor Regulation
Géraldine Poisnel, Martine Dhilly, Reynald Le Boisselier, Louisa Barre and Danièle DebruyneJournal of Pharmacological Sciences 110 (1) 36 (2009)
https://doi.org/10.1254/jphs.08249FP